Login

2016 Career Development Workshop (co-organized by CBA, SCBA and NIH-CSSA)

2016 Career Development Workshop (co-organized by CBA, SCBA and NIH-CSSA)

 

CBA 2016职业发展论坛于4月30日

在JHU的Shady Grove校区成功举办

 

2016 Career Development Workshop

co-organized by CBA, SCBA and NIH-CSSA
 

Diversified Opportunities to Boost Your Career
 

8:30 AM – 12:30 PM | Saturday, April 30, 2016
The Auditorium, Johns Hopkins Shady Grove Campus
(9601 Medical Center Dr, Rockville, MD 20850)

  ______________________________________________________________________________________

 

由美国华人生物医药科技协会(Chinese Biopharmaceutical Association-USA, CBA)主办、美洲华人生物科学学会(Society of Chinese Bioscientists in America, SCBA) 和美国国立卫生研究院中国学生学者联谊会(Chinese Students and Scholars Association at the National Institute of Health, NIH-CSSA) 协办的2016年度职业发展论坛于4月30日在约翰霍普金斯大学Shady Grove校区隆重举行。该活动吸引了近两百名生物医药领域人士的参与。

 

本届职业论坛由NIH研究员杨春章博士和ASQ509 Biomed/Biotech SIG主席George Chang博士主持。首先,CBA候任会长、阿斯利康质量和技术总监姜绪荣博士代表CBA致开幕词,欢迎所有人到场参会。其后,MedImmune生物医药开发主任科学家Min Zhu博士、Mancini & Chang 律所的创始人Sam Hsien-Cheng Chang律师和合伙人Richard W. Chang律师、George Chang博士、GSK疫苗技术研发部门的高级顾问Timothy Schofiled博士以及Blue Venture Investigators主管Steven Chen等数位来自企业界、法律界、政府机关以及投资界的精英人才,热烈地讨论了当前生物医药行业中的诸多热门话题,并以自身的职业发展经历为例,与在场的观众们分享了他们在学业、事业和创业历程中的独到见解。

 

作为CBA一年一度的重头戏之一,年度职业发展论坛依靠其精英的特邀嘉宾、精心的活动组织和精良的内容设计,多年来受到华府华人社区的广泛好评,影响力巨大。为了给参会者提供更全面多样的求职帮助,本届论坛不但邀请了来自不同领域的多位生物医药精英现场演讲,还设立了HR Showcase,由来自MedImmunie、Novavax和GSK公司的HR进行现场介绍。此外,论坛还为求职者提供了现场的简历修改指导。

 

Distinguished Speakers include:

 

Ziping Wei, Ph.D

 

Xu-Rong Jiang,Ph.D.
CBA President-Elect
Director of Quality and Technical of AstraZeneca BioVentures, Global Biologics Operation
 

Dr. Xu-Rong Jiang is currently a Director of Quality and Technical for AstraZeneca BioVentures, Global Biologics Operation. Prior to his current responsibility, Dr. Jiang had served as an Associate Director in Analytical Biotechnology at MedImmune since 2008. He headed the Biological Development Group in support of biologics analytical method development for IND filing, GMP testing, technology transfer and process development. Prior to MedImmune, Dr. Jiang had been a Principal Scientist in Process & Analytical Sciences at Amgen for nearly 6 years where his group was responsible for development, qualification, validation of potency assays for biologics development. Dr. Jiang was a Senior Scientist at Geron Corporation focusing on gene and cell therapy, high throughput screening, and regenerative medicine with embryonic stem cells. Dr. Jiang received his PhD degree in Molecular Cell Biology from University of London. He also had an MD in Hematology from China Medical University. He is an Associate Director for CASSS, an International Separation Science Society. He has been a member of Scientific Organizing Committee for CASSS Bioassays since 2011, and as an organizing committee member for the Cell-based Assay Action Program Committee, American Association for Pharmaceutical Scientists. Dr. Jiang has been the President-elect and a member of Board of Director of the Chinese Biopharmaceutical Association-USA in 2015-2016. 

Samuel T. Mok

 

Min Zhu, PhD
Principle Scientist of MedImmune
Biopharmaceutical Development
 

Dr. Min Zhu has over 12 years of biopharmaceutical industry experience in process development, characterization, manufacturing, and validation support. Currently, Dr. Zhu is a Principle Scientist of Biopharmaceutical Development at MedImmune, a member of the Astra Zeneca group. Before joining MedImmune, she worked as a Process Engineer at Lonza. Previously, Dr. Zhu was a Senior Scientist of Critical Reagent and Formulation, responsible for antibody and conjugation reagent development and GMP manufacturing. Dr. Zhu has served in several non-profit organizations as a director in Board, a member of Executive committee or a volunteer in Parents’ Committee. She is an active speaker in professional conferences, as well the career development workshop.Dr. Zhu received the B.S. and M.S. degree in Chemistry from Fudan University and Ph.D. in Chemistry from Nankai University in China. She was a post-doc fellow at Max-Plank Institute and University of California, Santa Cruz. 

Wanjun Chen, MD

 

Timothy Schofield, Ph.D
Senior Advisor of GSK Vaccines, Technical Research & Development Department
 

Mr. Timothy Schofield is a Senior Advisor in the Technical Research & Development department at GSK Vaccines. Prior to joining GSK Tim worked at MedImmune as a Senior Fellow in the Analytical Biotechnology Sciences & Strategy department, at Arlenda, Inc. as Managing Director and Head of Nonclinical Statistics, and at the Merck Research Laboratories heading the Nonclinical Statistics unit. Tim is a member of the USP Statistics Expert Committee and has participated in industry initiatives related to Quality by Design, analytical method development and validation, stability and specifications. He is author or contributor to more than 50 publications, textbook chapters and regulatory guidances. Tim received a Master of Arts degree in Statistics and Operations Research in 1976 from the Wharton School of the University of Pennsylvania in Philadelphia.

Qiao Yu. Bobo, PHD

C.J. George Chang, DVM, PhD

Chair of American Society for Quality Section 509

Dr. C.J. George Chang is a veterinarian, veterinary pathologist, and toxicologist by training and a self-trained analytical chemist. He serves a senior pharmacologist at FDA/CDER and is responsible for nonclinical review for oncology drug applications. Before joining FDA, Dr. Chang had worked in pharmaceutical, bioinformatics, contract research, and consumer product industries. He is the inaugural/current chair for biomed/biotech SIG of local American Society for Quality (http://www.asq509.org/ht/d/sp/i/31557/pid/31557), a past president of local Chinese American Professionals Assoc., and a past board member of local Monte Jade Sci/Tech Assoc., National Capital Area of Soc. of Quality Assurance, Association for Government Toxicology, Nat. Taiwan U. Alumni Assoc., and CCACC. 

Milos Dokmanovic, Ph.D.

 

Steven Chen
Blu Venture Investors
 

Mr. Steven Chen is a member of Blu Venture investors, an Angel Investor Group makes investments in early-stage companies in the Mid-Atlantic region with focus on technology companies including cyber security, analytics, Web 2.0, B2B and B2C software companies and new disruptive technologies in material, chemical, and biological sciences.Steven Chen’s experience includes CEO of an Intel Capital portfolio company, CTO and M&A for a $150M public company, $300M+ SBIR contracts, chairman of an IEEE standard working group. He is currently founder of 2 startups, investor of 6 companies and advisor for multiple companies. Steven is the Founder and Board Director of Totus-Solutions (physical security and wireless), Cofounder and Chairman of Power Fingerprinting (cyber security), Chairman of Totus Strategic Partners, past president of Monte Jade DC, Chairman of IEEE 1451.5 Wireless Smart Sensor Networks and member of Mindshare Alumni and FounderCorps. Steve was the founder and CEO of 3eTI (an Intel Capital portfolio company, acquired by EFJohnson in 2006), and also served as CEO of Totus Solutions, Chairman of BioGreen, CTO of EFJohnson, and VP of PCB Piezotronics. He graduated from Tamkang University (BSEE) and SUNY Buffalo (MSEE).

Kun Yao

 

Sam Hsien-Cheng Chang
Co-founder and immigration and nationality lawyer of Wasserman, Mancini & Chang
 

Mr. Sam Hsien-Cheng Chang is co-founder and an immigration and nationality lawyer at Wasserman, Mancini & Chang, which was named one of America's Best Law Firms 2016 by U.S. News and World Reports, December 2015.Mr. Chang is a member of The District of Columbia Bar, Bar Association of the District of Columbia; American Bar Association, and American Immigration Lawyers Association. Sam has served as Co-Host of free call-in show, Immigration Law Today on World Today Cable TV, Comcast Montgomery County, Maryland, Channel 678, 1993- Present; Exclusive Immigration Consulting Lawyer for Chinese AOL, http://chinese.aol.com; Host, Free Legal Affairs Program, Channel 56, Fairfax, Virginia, 1989-1992; Secretary, Taiwan University Alumni Association, Washington D.C. Chapter, 1982-1983; General Counsel, Asian American Voters' Coalition, 1986-1987; Vice President of Chinese American Chamber of Commerce, 1988-present; General Counsel, Metro Washington Chinese Restaurant Association, 1988-present; Principal, Gaithersburg Chinese School, 1983-1984; President, U.S. Chinese Golf Association, 2001-2005. Sam is graduated from National Taiwan University, Taipei, Taiwan (LL.B., 1968) and Howard University (M.C.L., 1975) and was admitted to DC bar in 1981. Sam’s rating and awards: AV Peer Review Rated; Named Top 1% of all lawyers in the DC Metropolitan area by the Washingtonian Magazine, December 2007 and 2009.

Kun Yao

 

Richard W. Chang 
Junior Partner of 
Wasserman, Mancini & Chang 

 

Mr. Richard W. Chang is a junior partner at the law firm of Wasserman, Mancini & Chang, an "AV" rate firm that is also one of the oldest immigration law firms in the country. He currently heads the Litigation and Criminal Section. Richard W. Chang received his Juris Doctorate (JD) and his International Law Certificate at the Columbus School of Law at the Catholic University of America. He co-founded the DC Chapter of the National Association of Asian American Professionals (NAAAP-DC) in 1998. Richard was a contributing author for the Taiwan-AIT article in "The Visa Processing Guide" published by the American Immigration Lawyers Association (AILA). His article titled, “Proper Invalidation Of A Labor Certification By DHS, DOL Or DOS” was published on August 7, 2008 by www.ilw.com. Richard has chaired various committees with AILA-DC over the past few years. He was ranked as one of the Top Northeast Lawyer's by Amtrak Arrive Magazine and AVVO in Nov/Dec 2011.

 

Career Workshop Presentations:

 

Dr. Xurong Jiang's presentation

Dr. Min Zhu's presentation

Dr. Timothy Schofiled's presentation

Mr. Sam Hsien-Cheng Chang and Mr. Richard Chang's joint presentation

Dr. George Chang's presentation

Dr. Steven Chen's presentation

X